Happening yesterday, Novo Nordisk has just announced the availability of Wegovy® (semaglutide 2.4 mg) (MAL24126014AZ) in Malaysia, an adjunct treatment option for adults living with obesity and overweight who present with at least one weight-related comorbidity. This is made available against a backdrop of growing health concerns, with recent data from the National Health and Morbidity Survey (NHMS) 2023 revealing that nearly 54.4% of Malaysian adults are classified as living with overweight or obesity. From left: Prof. Dr Rohana Abdul Ghani, Emeritus Professor Dr Chan Siew Pheng, Dato' Sri Dr. Azhari Rosman and Dr. Praful Chakkarwar at the launch event. Obesity is a disease associated with more than 200 potential health complications, making it a ‘gateway’ disease to serious issues such as type 2 diabetes and cardiovascular disease. These conditions significantly impact an individual's life expectancy and overall quality of life. Wegovy® (Semaglutide 2.4mg), a key advancement ...
- Get link
- X
- Other Apps